Stockscreener 앱 받기
10.37
1.57%
0.16
시간 외 거래:
10.36
-0.010
-0.10%
Delcath Systems Inc 주식(DCTH)의 최신 뉴스
Is Delcath Systems Inc backed by strong institutional buyingLong Setup & Daily Growth Stock Investment Tips - baoquankhu1.vn
Market Catalysts: Is ODYS forming a bullish divergenceEarnings Performance Report & Real-Time Buy Signal Notifications - baoquankhu1.vn
Price-Driven Insight from (DCTH) for Rule-Based Strategy - Stock Traders Daily
Delcath Systems expects FY revenue of $85.2 million - MSN
Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade (NASDAQ:DCTH) - Seeking Alpha
Delcath Systems Reports Strong Preliminary 2025 Results - TipRanks
NY-based Delcath Systems expects Q4 2025 revenue to hit USD 20.7M - Medical Buyer
Aug Closing: Is Delcath Systems Inc subject to activist investor interestJuly 2025 Institutional & Target Return Focused Stock Picks - baoquankhu1.vn
Delcath Systems, Inc. (NASDAQ:DCTH) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Delcath Systems, Inc. (NASDAQ:DCTH) Q2 2025 Earnings Call Transcript - MSN
EBITDA per share of Delcath Systems, Inc. – DUS:DV3R - TradingView — Track All Markets
Delcath reports $85.2 million in 2025 revenue, strong cash position By Investing.com - Investing.com Nigeria
Delcath Systems (NASDAQ:DCTH) Stock Rating Upgraded by Wall Street Zen - MarketBeat
DCTH FinancialsIncome Statement - Quiver Quantitative
DCTH: HC Wainwright Reiterates Buy Rating with $30 Price Target - GuruFocus
HC Wainwright Reaffirms Buy Rating for Delcath Systems (NASDAQ:DCTH) - MarketBeat
Delcath Systems, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2025 - MarketScreener
Delcath Systems (DCTH) Exceeds Revenue Expectations in Q4 and Fu - GuruFocus
Delcath Systems announces preliminary fourth quarter and full year 2025 financial results - marketscreener.com
Delcath reports $85.2 million in 2025 revenue, strong cash position - Investing.com
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results - The AI Journal
Will Delcath Systems Inc. stock outperform Nasdaq indexWeekly Market Report & Fast Entry Momentum Alerts - ulpravda.ru
ETF Watch: Will Delcath Systems Inc. stock remain a Wall Street favoriteTrade Ideas & Reliable Price Breakout Signals - Улправда
How resilient is Delcath Systems Inc. stock in market downturnsJuly 2025 Retail & Weekly Top Gainers Alerts - ulpravda.ru
Will Delcath Systems Inc. stock remain a Wall Street favoriteMarket Volume Summary & Daily Technical Forecast Reports - Улправда
Shorts Report: Will Delcath Systems Inc stock remain a Wall Street favorite2025 Earnings Impact & Daily Growth Stock Investment Tips - Bộ Nội Vụ
Delcath Systems, Inc. (DCTH) Beats Q4 Earnings and Revenue Estimates - MSN
A Look At Delcath Systems (DCTH) Valuation After New Phase 3 FOCUS Subgroup Data On HEPZATO KIT - Sahm
Under the Radar: 3 Microcap Growers Passing a Tough Test - Benzinga
Will Delcath Systems Inc. stock sustain high P E ratios2026 world cup usa national team round of 16 key players high defensive line match prediction expert opinion - Улправда
Will New HEPZATO KIT Subgroup Data on Tumor Burden and Survival Change Delcath Systems' (DCTH) Narrative - Sahm
(DCTH) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Should New HEPZATO Subgroup Data and Delcath’s Targeted Strategy Require Action From DCTH Investors? - Yahoo Finance
Are options traders betting on a big move in Delcath Systems stock? - MSN
Delcath Systems Inc Stock Analysis and ForecastLong-Term Growth Stocks & Fast Growing Investment Plans - earlytimes.in
Hepzato Kit Safe, Effective in Metastatic, Unresectable Uveal Melanoma - Cure Today
Are Options Traders Betting on a Big Move in Delcath Systems Stock? - Nasdaq
Delcath Systems publishes results from subgroup analyses of FOCUS study - Yahoo Finance
Delcath’s HEPZATO shows consistent efficacy across patient subgroups By Investing.com - Investing.com Nigeria
Delcath Systems (DCTH) Reveals Key Findings from FOCUS Study Sub - GuruFocus
Delcath’s HEPZATO shows consistent efficacy across patient subgroups - Investing.com
Which metastatic uveal melanoma patients gain most from a liver-directed drug? - Stock Titan
Simplify Asset Management Inc. Increases Stock Position in Delcath Systems, Inc. $DCTH - MarketBeat
Glenmark Pharmaceuticals Limited (532296) Gets Regulatory ApprovalFibonacci Extensions & Build Wealth With Strategy - bollywoodhelpline.com
Book value per share of Delcath Systems, Inc. – MUN:DV3R - TradingView — Track All Markets
Bearish Setup: Is Delcath Systems Inc stock a smart buy before Fed meetingTrade Entry Summary & Advanced Technical Signal Analysis - Bộ Nội Vụ
Precision Trading with Delcath Systems Inc. (DCTH) Risk Zones - Stock Traders Daily
Delcath Systems, Inc. (NASDAQ:DCTH) is a favorite amongst institutional investors who own 51% - Yahoo Finance
Delcath Systems (STU:DV3R) EV-to-OCF : 19.88 (As of Dec. 21, 2025) - GuruFocus
Why Delcath Systems Inc. (DV3R) stock stays on buy lists2025 Biggest Moves & Entry Point Strategy Guides - bolumsonucanavari.com
Delcath Systems Earnings Notes - Trefis
Delcath Systems authorizes $25 million share repurchase program - MSN
0.42%
1.96%
자본화:
|
볼륨(24시간):